LifeSci Acquisition II Corp. (LSAQ)
Price:
9.01 USD
( - -0.18 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
LifeSci Acquisition II Corp. intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities in the healthcare industry. The company was founded in 2019 and is based in New York, New York.
NEWS
Why Is Science 37 (SNCE) Stock Up 9% Today?
investorplace.com
2023-03-13 08:41:32Science 37 (NASDAQ: SNCE ) stock is rising higher on Monday following news of inducement equity awards for its Metasite employees. According to a press release from Science 37, the awards were approved by its Board of Directors in November 2022.
Science 37 Holdings, Inc. (SNCE) CEO David Coman on Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
2022-03-22 10:44:05Science 37 Holdings, Inc. (SNCE) CEO David Coman on Q4 2021 Results - Earnings Call Transcript
Science 37: Pioneering Decentralized Clinical Trials
seekingalpha.com
2022-01-02 15:05:22Science 37 pioneered the concept of decentralized clinical trials. The Covid-19 pandemic drove more demand for DCTs.
'SPACs Attack' Recap: Looking Back At 5 SPAC Deals, Rumors And Top Headlines
benzinga.com
2021-05-08 16:16:41Last week featured five announced SPAC deals and several rumors. The week also had earnings from several well-known former SPACs.
U.S. IPO Weekly Recap: Breast Cancer Biotech Pops 158% In A 6-IPO Week
seekingalpha.com
2020-11-22 13:07:23In a scramble to go public ahead of the holiday, six IPOs and 15 SPACs went public this past week led by breast cancer biotech Olema Pharmaceuticals, which soared 158% on its first day. New filings continued to pour in, priming the IPO pipeline for an active end to 2020.
LifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public Offering
globenewswire.com
2020-11-20 13:51:00NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) -- LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company targeting the biopharma sector, announced today that it priced its initial public offering of 7,500,000 shares at $10.00 per share. The shares will begin trading today on the NASDAQ Capital Market (“NASDAQ”) under the symbol “LSAQ.”
No data to display
No data to display
Why Is Science 37 (SNCE) Stock Up 9% Today?
investorplace.com
2023-03-13 08:41:32Science 37 (NASDAQ: SNCE ) stock is rising higher on Monday following news of inducement equity awards for its Metasite employees. According to a press release from Science 37, the awards were approved by its Board of Directors in November 2022.
Science 37 Holdings, Inc. (SNCE) CEO David Coman on Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
2022-03-22 10:44:05Science 37 Holdings, Inc. (SNCE) CEO David Coman on Q4 2021 Results - Earnings Call Transcript
Science 37: Pioneering Decentralized Clinical Trials
seekingalpha.com
2022-01-02 15:05:22Science 37 pioneered the concept of decentralized clinical trials. The Covid-19 pandemic drove more demand for DCTs.
'SPACs Attack' Recap: Looking Back At 5 SPAC Deals, Rumors And Top Headlines
benzinga.com
2021-05-08 16:16:41Last week featured five announced SPAC deals and several rumors. The week also had earnings from several well-known former SPACs.
U.S. IPO Weekly Recap: Breast Cancer Biotech Pops 158% In A 6-IPO Week
seekingalpha.com
2020-11-22 13:07:23In a scramble to go public ahead of the holiday, six IPOs and 15 SPACs went public this past week led by breast cancer biotech Olema Pharmaceuticals, which soared 158% on its first day. New filings continued to pour in, priming the IPO pipeline for an active end to 2020.
LifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public Offering
globenewswire.com
2020-11-20 13:51:00NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) -- LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company targeting the biopharma sector, announced today that it priced its initial public offering of 7,500,000 shares at $10.00 per share. The shares will begin trading today on the NASDAQ Capital Market (“NASDAQ”) under the symbol “LSAQ.”